Liquidia Corporation Stock Price, News & Analysis

Liquidia Corporation (NASDAQ: LQDA) announced the pricing of an underwritten public offering of 9,803,922 shares at $5.10 per share, totaling approximately $50.0 million in gross proceeds. The offering is set to close on April 18, 2022, subject to customary conditions. The underwriters have a 30-day option to purchase an additional 1,470,588 shares. This offering is conducted under Liquidia's previously filed shelf registration statement with the SEC. BofA Securities is the sole book-running manager for this offering.

Liquidia Corporation (NASDAQ: LQDA) announced the commencement of an underwritten public offering of its common stock, with all shares sold by the company. The underwriters may purchase an additional 15% of the shares within 30 days at the offering price. The offering relies on a previously filed shelf registration statement and is subject to market conditions. BofA Securities is the sole book-running manager. The net proceeds will be used for corporate purposes, although specific details were not provided. Completion of the offering is uncertain.

Liquidia Corporation (NASDAQ: LQDA) announced the grant of a stock option for 2,000 shares to a newly hired non-executive employee as part of its 2022 Inducement Plan. This grant aligns with Nasdaq Listing Rule 5635(c)(4) and serves as an employment incentive. The option is exercisable at $6.94 per share, the closing price on March 21, 2022, and has a ten-year term with a vesting schedule over four years.

Liquidia focuses on developing treatments for pulmonary hypertension using its PRINT® Technology and has launched YUTREPIA™ for pulmonary arterial hypertension.

Liquidia Corporation (NASDAQ: LQDA) announced key updates including the tentative FDA approval of YUTREPIA™ (treprostinil) inhalation powder for treating pulmonary arterial hypertension (PAH). The company plans to launch YUTREPIA in late 2022, pending final FDA approval. Revenue surged to $12.9 million for 2021 from $0.7 million in 2020, driven by increased sales of Treprostinil Injection. Legal victories in ongoing litigation with United Therapeutics further strengthen their market position.

Liquidia Corporation (LQDA) announced it will report its full-year 2021 financial results on March 17, 2022. A conference call is scheduled for 8:30 a.m. ET to discuss these results and provide a corporate update. The call can be accessed via phone and will also be available for live streaming on Liquidia's website. The company specializes in biopharmaceuticals, particularly treatments for pulmonary hypertension, and has received tentative FDA approval for its product YUTREPIA™ (treprostinil) inhalation powder.

Pathalys Pharma, a late-stage biopharmaceutical company, has been established with seed financing from DaVita Venture Group and Catalys Pacific. The company focuses on chronic kidney disease (CKD) treatments, starting with the investigational drug upacicalcet, which has demonstrated efficacy in Japan. Pathalys plans to conduct two phase 3 clinical trials in the U.S. for upacicalcet to treat secondary hyperparathyroidism in hemodialysis patients. Neal Fowler, a former CEO at Liquidia, has been appointed as CEO, enhancing the leadership team's industry experience.

Liquidia Corporation (NASDAQ: LQDA) announced the grant of an inducement stock option for 25,700 shares of its common stock to a new non-executive employee. This grant, made under the 2022 Inducement Plan, serves as a key part of the employee's compensation package. The stock option is exercisable at a price of $5.47 per share, matching the closing price on the grant date, February 22, 2022. It features a ten-year term and vests over four years with specific vesting conditions.

Liquidia Corporation (NASDAQ: LQDA) has secured a new debt facility with Silicon Valley Bank (SVB) amounting to up to $40 million, announced on January 7, 2022. The initial $20 million has been funded, allowing Liquidia to retire existing debt and add $9.5 million to its cash reserves. Future tranches are contingent on regulatory milestones related to its product YUTREPIA™. The debt facility will mature by December 1, 2025, with interest-only payments through December 2023. This capital aims to support pre-commercial activities and the anticipated launch of YUTREPIA.

Liquidia Corporation (NASDAQ: LQDA) appointed Dr. Roger Jeffs as CEO, effective January 3, 2022. He succeeds Damian deGoa, who will remain on the board until January 31, 2022. Dr. Jeffs, who has extensive experience in drug development, aims to optimize the upcoming launch of YUTREPIA™ (treprostinil) inhalation powder, which recently received tentative FDA approval. The company focuses on pulmonary arterial hypertension and plans to leverage its PRINT® Technology for future developments. This leadership change comes as Liquidia prepares for potential profitability with YUTREPIA's launch.